Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Abstract Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demon...

Full description

Bibliographic Details
Main Authors: Randi Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison
Format: Article
Language:English
Published: Nature Publishing Group 2018-11-01
Series:Scientific Reports
Subjects:
Mavoglurant
Core Studies
Fragile X Mental Retardation Protein (FMRP)
Repetitive Behavior Scale-Revised (RBS-R)
Extension Study Baseline
Online Access:https://doi.org/10.1038/s41598-018-34978-4

Internet

https://doi.org/10.1038/s41598-018-34978-4

Similar Items